Stock comparison
Elanco Animal Health
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ELAN
Elanco Animal Health
Market cap
$10.85B
Sector
Healthcare
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ELAN | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 32F | 72B | RMD |
| Benjamin Graham | 31F | 75B | RMD |
| Philip Fisher | 30F | 75B | RMD |
| Peter Lynch | 6F | 58C | RMD |
| Joel Greenblatt | 40D | 47D | RMD |
| Charlie Munger | 32F | 69B | RMD |
| Terry Smith | 23F | 73B | RMD |
Side-by-side metrics
| Metric | ELAN | RMD |
|---|---|---|
| Market cap | $10.85B | $30.18B |
| P/E (TTM) | - | 19.6x |
| EV/EBIT | 53.5x | 17.1x |
| ROIC (TTM) | 3.77% | 19.63% |
| Gross margin | 49.44% | 61.69% |
| Net margin | -4.95% | 27.44% |
| Revenue CAGR 5y | -0.26% | 12.64% |
| EPS CAGR 5y | - | 30.73% |
| Debt / Equity | 0.6x | 0.1x |
| Dividend yield | 0.0% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ELAN leads on
- P/E (TTM)-vs 19.6x+148%
RMD leads on
- Net margin27.44%vs -4.95%+118%
- Revenue CAGR 5y12.64%vs -0.26%+102%
- Dividend yield1.14%vs 0.0%+100%
- ROIC (TTM)19.63%vs 3.77%+81%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.